Literature DB >> 21762797

Molecular determinants that regulate plasma membrane association of HIV-1 Gag.

Vineela Chukkapalli1, Akira Ono.   

Abstract

Human immunodeficiency virus type 1 assembly is a multistep process that occurs at the plasma membrane (PM). Targeting and binding of Gag to the PM are the first steps in this assembly process and are mediated by the matrix domain of Gag. This review highlights our current knowledge on viral and cellular determinants that affect specific interactions between Gag and the PM. We will discuss potential mechanisms by which the matrix domain might integrate three regulatory components, myristate, phosphatidylinositol-(4,5)-bisphosphate, and RNA, to ensure that human immunodeficiency virus type 1 assembly occurs at the PM.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21762797      PMCID: PMC3139151          DOI: 10.1016/j.jmb.2011.04.015

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  120 in total

1.  Plasma membrane rafts play a critical role in HIV-1 assembly and release.

Authors:  A Ono; E O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells.

Authors:  P D Bieniasz; B R Cullen
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Entropic switch regulates myristate exposure in the HIV-1 matrix protein.

Authors:  Chun Tang; Erin Loeliger; Paz Luncsford; Isaac Kinde; Dorothy Beckett; Michael F Summers
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

4.  Gag localization and virus-like particle release mediated by the matrix domain of human T-lymphotropic virus type 1 Gag are less dependent on phosphatidylinositol-(4,5)-bisphosphate than those mediated by the matrix domain of HIV-1 Gag.

Authors:  Jingga Inlora; Vineela Chukkapalli; David Derse; Akira Ono
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

5.  Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein.

Authors:  A Cimarelli; J Luban
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

6.  Sequence-specific interaction between HIV-1 matrix protein and viral genomic RNA revealed by in vitro genetic selection.

Authors:  P Purohit; S Dupont; M Stevenson; M R Green
Journal:  RNA       Date:  2001-04       Impact factor: 4.942

7.  Evidence that productive human immunodeficiency virus type 1 assembly can occur in an intracellular compartment.

Authors:  Anjali Joshi; Sherimay D Ablan; Ferri Soheilian; Kunio Nagashima; Eric O Freed
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

8.  Analysis of human immunodeficiency virus type 1 matrix binding to membranes and nucleic acids.

Authors:  Ayna Alfadhli; Amelia Still; Eric Barklis
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

9.  Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix domain.

Authors:  Vineela Chukkapalli; Seung J Oh; Akira Ono
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

Review 10.  Phosphoinositide signaling: new tools and insights.

Authors:  Tamas Balla; Zsofia Szentpetery; Yeun Ju Kim
Journal:  Physiology (Bethesda)       Date:  2009-08
View more
  71 in total

Review 1.  How HIV-1 Gag assembles in cells: Putting together pieces of the puzzle.

Authors:  Jaisri R Lingappa; Jonathan C Reed; Motoko Tanaka; Kasana Chutiraka; Bridget A Robinson
Journal:  Virus Res       Date:  2014-07-24       Impact factor: 3.303

2.  The C-terminal p6 domain of the HIV-1 Pr55Gag precursor is required for specific binding to the genomic RNA.

Authors:  Noé Dubois; Keith K Khoo; Shannon Ghossein; Tanja Seissler; Philippe Wolff; William J McKinstry; Johnson Mak; Jean-Christophe Paillart; Roland Marquet; Serena Bernacchi
Journal:  RNA Biol       Date:  2018-08-04       Impact factor: 4.652

Review 3.  Role of host tRNAs and aminoacyl-tRNA synthetases in retroviral replication.

Authors:  Danni Jin; Karin Musier-Forsyth
Journal:  J Biol Chem       Date:  2019-01-30       Impact factor: 5.157

4.  How HIV finds the door.

Authors:  Matthew Scott Lalonde; Wesley I Sundquist
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-01       Impact factor: 11.205

5.  A temporospatial map that defines specific steps at which critical surfaces in the Gag MA and CA domains act during immature HIV-1 capsid assembly in cells.

Authors:  Bridget A Robinson; Jonathan C Reed; Clair D Geary; J Victor Swain; Jaisri R Lingappa
Journal:  J Virol       Date:  2014-03-12       Impact factor: 5.103

6.  A conformational transition observed in single HIV-1 Gag molecules during in vitro assembly of virus-like particles.

Authors:  James B Munro; Abhinav Nath; Michael Färber; Siddhartha A K Datta; Alan Rein; Elizabeth Rhoades; Walther Mothes
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

7.  Solution Conformation of Bovine Leukemia Virus Gag Suggests an Elongated Structure.

Authors:  Dominic F Qualley; Sarah E Cooper; James L Ross; Erik D Olson; William A Cantara; Karin Musier-Forsyth
Journal:  J Mol Biol       Date:  2019-02-04       Impact factor: 5.469

Review 8.  The role of matrix in HIV-1 envelope glycoprotein incorporation.

Authors:  Philip R Tedbury; Eric O Freed
Journal:  Trends Microbiol       Date:  2014-06-02       Impact factor: 17.079

9.  HIV-1 Gag associates with specific uropod-directed microdomains in a manner dependent on its MA highly basic region.

Authors:  G Nicholas Llewellyn; Jonathan R Grover; Balaji Olety; Akira Ono
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

10.  Molecular Determinants Directing HIV-1 Gag Assembly to Virus-Containing Compartments in Primary Macrophages.

Authors:  Jingga Inlora; Vineela Chukkapalli; Sukhmani Bedi; Akira Ono
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.